Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019

Download as PDF

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it will report its financial results for the full year 2018 on Thursday, March 21, 2019.

The management team will host a conference call on March 21, 2019 in English at 2:30 pm EDT (New York time) / 7:30 pm CET (Paris time) to discuss the financial results and provide a corporate update.

To access the conference call, please use one of the following dial-in numbers and connect at least 5 minutes prior to the scheduled start time:
US: +1 646-722-4916
UK: +44 (0) 207 194 3759
FR: +33 (0)1 72 72 74 03
Followed by the PIN code: 89356541#

A slide presentation will be available in the "Investors / Shareholder Information/ Regulatory Documentation 2018" section of the Poxel website shortly before the conference call.

Following the live call, a replay will be available for 90 days. To access the replay, please use one of the following numbers:
US: +1 646-722-4969
UK: +44 20 3364 5147
FR: +33 (0)1 70 71 01 60
Followed by the PIN code: 418836924#

About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985

Investor relations / Media - EU/US
Trophic Communications
Gretchen Schweitzer or Stephanie May
may@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
NewCap
Alexia Faure/Nicolas Merigeau
poxel@newcap.eu
+33 1 44 71 94 94

Source: Poxel SA

Released March 11, 2019